Community Acquired Pneumonia - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 64 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Community Acquired Pneumonia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Community Acquired Pneumonia - Pipeline Review, H2 2014', provides an overview of the Community Acquired Pneumonia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Community Acquired Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community Acquired Pneumonia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Community Acquired Pneumonia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Community Acquired Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Community Acquired Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Community Acquired Pneumonia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Community Acquired Pneumonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Community Acquired Pneumonia Overview 6
Therapeutics Development 7
Pipeline Products for Community Acquired Pneumonia - Overview 7
Pipeline Products for Community Acquired Pneumonia - Comparative Analysis 8
Community Acquired Pneumonia - Therapeutics under Development by Companies 9
Community Acquired Pneumonia - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Community Acquired Pneumonia - Products under Development by Companies 13
Community Acquired Pneumonia - Companies Involved in Therapeutics Development 14
AstraZeneca PLC 14
Biotest AG 15
C10 Pharma AS 16
Durata Therapeutics, Inc. 17
Kyorin Pharmaceutical Co., Ltd. 18
Paratek Pharmaceuticals, Inc. 19
TaiGen Biotechnology Co., Ltd. 20
Community Acquired Pneumonia - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
BT-086 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
C-10 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
dalbavancin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
KRPAM-1977X - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
nemonoxacin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
omadacycline - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules for SSTI and CAP Infections - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ticagrelor - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Community Acquired Pneumonia - Recent Pipeline Updates 45
Community Acquired Pneumonia - Dormant Projects 59
Community Acquired Pneumonia - Discontinued Products 60
Community Acquired Pneumonia - Product Development Milestones 61
Featured News & Press Releases 61
Oct 03, 2014: FDA Grants Durata Therapeutics a Special Protocol Agreement for Its Phase 3 Study of DALVANCE in Hospitalized Community-Acquired Pneumonia 61
May 16, 2013: TaiGen Biotechnology Submits New Drug Application For Nemonoxacin In Taiwan And China 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 64
Disclaimer 64

List of Tables
Number of Products under Development for Community Acquired Pneumonia, H2 2014 7
Number of Products under Development for Community Acquired Pneumonia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Community Acquired Pneumonia - Pipeline by AstraZeneca PLC, H2 2014 14
Community Acquired Pneumonia - Pipeline by Biotest AG, H2 2014 15
Community Acquired Pneumonia - Pipeline by C10 Pharma AS, H2 2014 16
Community Acquired Pneumonia - Pipeline by Durata Therapeutics, Inc., H2 2014 17
Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2014 18
Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 19
Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Community Acquired Pneumonia Therapeutics - Recent Pipeline Updates, H2 2014 45
Community Acquired Pneumonia - Dormant Projects, H2 2014 59
Community Acquired Pneumonia - Discontinued Products, H2 2014 60